Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs). This is an ASCO Meeting Abstract from the 2021 ASCO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback